New combo pill attack targets genetic weakness in stubborn myeloma

This study tests two oral drugs, mirdametinib and sirolimus, given together to people with a type of blood cancer called multiple myeloma that has come back or not responded to treatment. The cancer must have specific gene changes (KRAS or NRAS). The trial has two parts: first to find a safe dose, then to see how well the combination works. About 54 adults will take the pills daily for up to a year, with regular checkups and follow-up for 4 more years.